Literature DB >> 8062572

Early, routine paralysis for intracranial pressure control in severe head injury: is it necessary?

J K Hsiang1, R M Chesnut, C B Crisp, M R Klauber, B A Blunt, L F Marshall.   

Abstract

OBJECTIVE: To investigate the efficacy of early, routine use of neuromuscular blocking agents for intracranial pressure management in patients with severe head injury.
DESIGN: Retrospective review of data from the Traumatic Coma Data Bank. The Traumatic Coma Data Bank was a collaborative project of the National Institute of Neurological Disorders and Stroke that involved four Level I trauma centers. The Traumatic Coma Data Bank prospectively collected data on 1,030 severe head-injured patients (Glasgow Coma Score of < or = 8) between 1984 and 1987.
SETTING: Four Level I trauma centers coordinated by the National Institute of Neurological Disorders and Stroke. PATIENTS: A total of 514 Traumatic Coma Data Bank patients who met study inclusion criteria were divided into two groups: group 1 consisted of 239 patients who were pharmacologically paralyzed starting within the first intensive care unit (ICU) shift or < or = 6 hrs into the second shift and lasting for at least 12 hrs. Group 2 contained the remaining 275 patients who did not fulfill these criteria.
MEASUREMENTS AND MAIN RESULTS: We analyzed the acute care course of these patients from the time of injury through admission, resuscitation, and ICU stay, as well as their rehabilitation follow-up results for < or = 1 yr. These two groups did not differ significantly regarding admission intracranial computed tomography diagnosis, admission Glasgow motor score, percentage of monitored time that intracranial pressure was > or = 20 mm Hg, or frequency of initial intracranial pressure > or = 20 mm Hg. In group 2, more patients were aged > 40 yrs (24% vs. 15% in group 1) or had admission hypotension (33% in group 2 vs. 25% in group 1). Multivariate regression analysis showed that ICU stay was significantly longer in group 1 (mean 7.76 days) than group 2 (mean 4.84 days; p < .001). The occurrence of pneumonia was significantly higher in group 1 (29% vs. 15%, p < .001). There was a tendency toward a higher occurrence of sepsis in group 1, but this difference did not reach statistical significance (11% vs. 7%, p = .08). The final Glasgow Outcome Scale scores for the two groups were not significantly different in those survivors with good and moderate outcomes. Although there were more deaths in group 2 (39% vs. 24%, p < .001), there were more vegetative or severely disabled survivors in group 1 (8% vs. 4% and 21% vs. 13%, respectively).
CONCLUSIONS: Our findings suggest that early, routine, long-term use of neuromuscular blocking agents in patients with severe head injuries to manage intracranial pressure does not improve overall outcome and may actually be detrimental because of the prolongation of their ICU stay and the increased frequency of extracranial complications associated with pharmacologic paralysis. We suggest that routine early management of the head-injured patient in the ICU should be accomplished using sedation alone and that neuromuscular blockade should be generally reserved for patients with intracranial hypertension who require escalation of treatment intensity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8062572     DOI: 10.1097/00003246-199409000-00019

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  16 in total

1.  Raised intracranial pressure.

Authors:  Laurence T Dunn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-09       Impact factor: 10.154

Review 2.  Critical care issues in the early management of severe trauma.

Authors:  Alberto Garcia
Journal:  Surg Clin North Am       Date:  2006-12       Impact factor: 2.741

Review 3.  New concepts in treatment of pediatric traumatic brain injury.

Authors:  Jimmy W Huh; Ramesh Raghupathi
Journal:  Anesthesiol Clin       Date:  2009-06

4.  Management of pediatric traumatic brain injury.

Authors:  Haifa Mtaweh; Michael J Bell
Journal:  Curr Treat Options Neurol       Date:  2015-05       Impact factor: 3.598

Review 5.  The role of neuromuscular blockade in patients with traumatic brain injury: a systematic review.

Authors:  Filippo Sanfilippo; Cristina Santonocito; Tonny Veenith; Marinella Astuto; Marc O Maybauer
Journal:  Neurocrit Care       Date:  2015-04       Impact factor: 3.210

6.  Effect of administration of neuromuscular blocking agents in children with severe traumatic brain injury on acute complication rates and outcomes: a secondary analysis from a randomized, controlled trial of therapeutic hypothermia.

Authors:  Katherine H Chin; Michael J Bell; Stephen R Wisniewski; Goundappa K Balasubramani; Patrick M Kochanek; Sue R Beers; S Danielle Brown; P David Adelson
Journal:  Pediatr Crit Care Med       Date:  2015-05       Impact factor: 3.624

7.  Use of high frequency oscillatory ventilation (HFOV) in neurocritical care patients.

Authors:  Stacey S Bennett; Carmelo Graffagnino; Cecil O Borel; Michael L James
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

8.  Endotracheal lidocaine in preventing endotracheal suctioning-induced changes in cerebral hemodynamics in patients with severe head trauma.

Authors:  Federico Bilotta; Giovanna Branca; Arthur Lam; Vincenzo Cuzzone; Andrea Doronzio; Giovanni Rosa
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

9.  Severe agitation among ventilated medical intensive care unit patients: frequency, characteristics and outcomes.

Authors:  Jeffery C Woods; Lorraine C Mion; Jason T Connor; Florence Viray; Lisa Jahan; Cecilia Huber; Renee McHugh; Jeffrey P Gonzales; James K Stoller; Alejandro C Arroliga
Journal:  Intensive Care Med       Date:  2004-02-14       Impact factor: 17.440

10.  The effect of single-dose and continuous skeletal muscle paralysis on respiratory system compliance in paediatric intensive care patients.

Authors:  M B Schindler; D J Bohn; A C Bryan
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.